Yajamanam Badrinath

Haematologic and immunophenotypic profile of acute myeloid leukemia : an experience of Tata Memorial Hospital

C Nair, Subhasis Ghosh, S. C. Shinde et al. · Indian Journal of Cancer · 2003 · 77 citations

Hematological Malignancy, Immunohematology, Laboratory Hematology +15

A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐10⁶and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients

Prashant Tembhare, Papagudi Ganesan Subramanian, Sitaram Ghogale et al. · Cytometry Part B Clinical Cytometry · 2019 · 74 citations · Full text

Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000

Prashant Tembhare, Sitaram Ghogale, Nisha Ghatwai et al. · Cytometry Part B Clinical Cytometry · 2016 · 63 citations · Full text

Betulinic acid induces apoptosis in human chronic myelogenous leukemia (CML) cell line K-562 without altering the levels of Bcr-Abl

D.V. Raghuvar Gopal, A A Narkar, Yajamanam Badrinath et al. · Toxicology Letters · 2004 · 58 citations

Hematological Malignancy, Apoptosis, Immunology +7

Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy

Prashant Tembhare, Harshini Sriram, Twinkle Khanka et al. · Journal for ImmunoTherapy of Cancer · 2020 · 41 citations · Full text